Prognostic Analysis of Lung Squamous Cell Carcinoma Patients with Second Primary Malignancies: a SEER Database Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Mar 6

PMID 38444672

Authors

Weiqing Han

Silin Wang

Lang Su

Jianjun Xu

Yiping Wei

Affiliations

Soon will be listed here.

Abstract

Background: As lung squamous cell carcinoma (LUSC) patients are at increased risk of developing a second primary cancer, this complicates the patient's condition and thus makes prognostic assessment more difficult, posing a significant prognostic challenge for clinicians. Our goal was to assess the prognosis of LUSC patients with a second primary tumor, and provide insights into appropriate therapy and monitoring strategies.

Methods: Data was obtained for LUSC patients from the Surveillance, Epidemiology, and End Results (SEER) database. The LUSC patients were divided into three groups (LS-SPM, OT-LUSC and LUSC-only). Univariate and stratified analyses were performed for the baseline and clinical characteristics of the participants. Multiple regression and Kaplan-Meier survival analyses were also performed, followed by a final life table analysis.

Results: In our sample of 101,626 patients, the HR for OS in the LS-SPM group was 0.40 in univariate analysis. Kaplan-Meier survival curves showed that LS-SPM patients had considerably longer lifespans compared to the other groups. The LS-SPM patients had median and mean survival times of 64 months and 89.11 months. Unadjusted and adjusted multiple regression analyses showed that LS-SPM patients had a superior survival compared to LUSC-only and OT-LUSC groups.

Conclusion: LS-SPM patients have a good prognosis with aggressive therapy and immune monitoring. The present study offers novel insights into the pathophysiological causes and treatments for LS-SPM.

Citing Articles

Impact of radiotherapy on second primary lung cancer incidence and survival in esophageal cancer survivors.

Lu J, Chen D, Shen Z, Gao L, Kang M Sci Rep. 2024; 14(1):17720.

PMID: 39085347 PMC: 11291913. DOI: 10.1038/s41598-024-67753-9.

References

Jones C, Cummings I, Shipolini A, McCormack D . Does surgery improve prognosis in patients with small-cell lung carcinoma?. Interact Cardiovasc Thorac Surg. 2012; 16(3):375-80. PMC: 3568800. DOI: 10.1093/icvts/ivs475. View

Li C, Liu J, Lin J, Li Z, Shang X, Wang H . Poor survival of non-small-cell lung cancer patients with main bronchus tumor: a large population-based study. Future Oncol. 2019; 15(24):2819-2827. DOI: 10.2217/fon-2019-0098. View

Coyte A, Morrison D, McLoone P . Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer. 2014; 14:272. PMC: 4005906. DOI: 10.1186/1471-2407-14-272. View

Suit H, Goldberg S, Niemierko A, Ancukiewicz M, Hall E, Goitein M . Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res. 2007; 167(1):12-42. DOI: 10.1667/RR0527.1. View

Jia H, Li Q, Yuan J, Sun X, Wu Z . Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis. Oncologist. 2020; 25(4):e644-e650. PMC: 7160402. DOI: 10.1634/theoncologist.2019-0266. View

Maresova P, Javanmardi E, Barakovic S, Barakovic Husic J, Tomsone S, Krejcar O . Consequences of chronic diseases and other limitations associated with old age - a scoping review. BMC Public Health. 2019; 19(1):1431. PMC: 6823935. DOI: 10.1186/s12889-019-7762-5. View

Ko K, Huang H, Chen Y, Chang H, Tsai W, Huang T . Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy. J Cancer Res Clin Oncol. 2020; 146(12):3323-3332. DOI: 10.1007/s00432-020-03310-x. View

Osarogiagbon R, Yu X . Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database. J Thorac Oncol. 2012; 7(12):1798-1806. DOI: 10.1097/JTO.0b013e31827457db. View

Khanal A, Lashari B, Kruthiventi S, Arjyal L, Bista A, Rimal P . The risk of second primary malignancy in patients with stage Ia non-small cell lung cancer: a U.S. population-based study. Acta Oncol. 2017; 57(2):239-243. DOI: 10.1080/0284186X.2017.1390250. View

10.

Kadambi S, Loh K, Dunne R, Magnuson A, Maggiore R, Zittel J . Older adults with cancer and their caregivers - current landscape and future directions for clinical care. Nat Rev Clin Oncol. 2020; 17(12):742-755. PMC: 7851836. DOI: 10.1038/s41571-020-0421-z. View

11.

Rodrigues P, Patel S, Harewood L, Olan I, Vojtasova E, Syafruddin S . NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis. Cancer Discov. 2018; 8(7):850-865. PMC: 6031301. DOI: 10.1158/2159-8290.CD-17-1211. View

12.

Buiatti E, Crocetti E, Acciai S, Gafa L, Falcini F, Milandri C . Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer. 1998; 33(11):1829-34. DOI: 10.1016/s0959-8049(97)00173-1. View

13.

Zandman-Goddard G, Peeva E, Shoenfeld Y . Gender and autoimmunity. Autoimmun Rev. 2007; 6(6):366-72. DOI: 10.1016/j.autrev.2006.10.001. View

14.

Yang J, Terebelo H, Zonder J . Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol. 2012; 2012:801495. PMC: 3407607. DOI: 10.1155/2012/801495. View

15.

Palumbo A, Bringhen S, Kumar S, Lupparelli G, Usmani S, Waage A . Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014; 15(3):333-42. DOI: 10.1016/S1470-2045(13)70609-0. View

16.

Berrington de Gonzalez A, Curtis R, Kry S, Gilbert E, Lamart S, Berg C . Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011; 12(4):353-60. PMC: 3086738. DOI: 10.1016/S1470-2045(11)70061-4. View

17.

van der Straten L, Levin M, Dinnessen M, Visser O, Posthuma E, Doorduijn J . Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood Cancer J. 2023; 13(1):15. PMC: 9837130. DOI: 10.1038/s41408-023-00784-z. View

18.

Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E . Multiple tumours in survival estimates. Eur J Cancer. 2009; 45(6):1080-94. DOI: 10.1016/j.ejca.2008.11.030. View

19.

Choi M, Kadara H, Zhang J, Parra E, Rodriguez-Canales J, Gaffney S . Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol. 2017; 28(1):83-89. PMC: 6246501. DOI: 10.1093/annonc/mdw437. View

20.

Donin N, Kwan L, Lenis A, Drakaki A, Chamie K . Second primary lung cancer in United States Cancer Survivors, 1992-2008. Cancer Causes Control. 2019; 30(5):465-475. DOI: 10.1007/s10552-019-01161-7. View